Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder CancerMax Kates, Trinity J. Bivalacqua, Thomas R. Nirschl et al.|Cancer Immunology Research|2017Cited by 77
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157Noah M. Hahn, Daniel M. Geynisman, Trinity J. Bivalacqua et al.|Clinical Cancer Research|2016Cited by 72
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerRussell E.N. Becker, Trinity J. Bivalacqua, Alexa Meyer et al.|European Urology|2020Cited by 72
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M. Hahn, Hristos Z. Kaimakliotis, Michael A. O’Donnell et al.|European Urology|2023Cited by 58
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 ImmunotherapyEmma Bigelow, Mark Yarchoan, Alex S. Baras et al.|Cancer Informatics|2022Cited by 8